The new capital is provided by KU Leuven Research & Development (LRD) and the European Investment Fund (EIF), whose contribution is supported under the European Commission’s InvestEU initiative, as well as by the Gemma Frisius Fund (GFF). It will be used to transform groundbreaking biomedical discoveries from both biotech companies and especially academic research groups at KU Leuven and other universities, into new medicines that improve people’s lives worldwide.
KU Leuven centre for drug design and discovery raises €70.5M for its fourth fund from the European Investment Fund
